Ziopharm CAO Kevin Lafond to exit Nov 8 amid restructuring

Alaunos Therapeutics, Inc.

Kevin G. Lafond, Sr. VP Finance, CAO and Treasurer, separating effective Nov 8, 2021.
Severance payment of approximately $0.2 million upon separation.
Departure is part of a restructuring to advance the TCR program.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kevin G. Lafond

Sr. Vice President Finance, Chief Accounting Officer and Treasurer

TCRT · Alaunos Therapeutics, Inc.

Effective: 2021-11-08
Filed: October 1, 2021, 7:59 PM ET

Kevin G. Lafond, Sr. Vice President Finance, Chief Accounting Officer and Treasurer, is separating from the Company effective November 8, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin G. Lafond departed as Sr. Vice President Finance, Chief Accounting Officer and Treasurer at Alaunos Therapeutics, Inc..

Action: separating
Role: Sr. Vice President Finance, Chief Accounting Officer and Treasurer

Exact text from the filing

Kevin G. Lafond, Sr. Vice President Finance, Chief Accounting Officer and Treasurer, is separating from the Company effective November 8, 2021

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-001975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.